WINSTEAD DWIGHT 4
4 · ONCOGENEX PHARMACEUTICALS, INC. · Filed May 18, 2010
Insider Transaction Report
Form 4
WINSTEAD DWIGHT
Director
Transactions
- Sale
Common Stock
2010-05-17$18.53/sh−23,855$442,148→ 0 total - Exercise/Conversion
Stock option (right to buy)
2010-05-17−8,260→ 0 totalExercise: $7.25From: 2009-05-12Exp: 2010-07-08→ Common Stock (8,260 underlying) - Exercise/Conversion
Common Stock
2010-05-17$2.69/sh+15,595$41,951→ 15,595 total - Exercise/Conversion
Common Stock
2010-05-17$7.25/sh+8,260$59,885→ 23,855 total - Exercise/Conversion
Stock option (right to buy)
2010-05-17−15,595→ 0 totalExercise: $2.69From: 2008-10-28Exp: 2015-10-28→ Common stock (15,595 underlying) - Sale
Common Stock
2010-05-13$19.20/sh−1,405$26,976→ 0 total - Exercise/Conversion
Common Stock
2010-05-13$2.69/sh+1,405$3,779→ 1,405 total - Exercise/Conversion
stock option (right to buy)
2010-05-13−1,405→ 15,595 totalExercise: $2.69From: 2008-10-28Exp: 2015-10-28→ Common Stock (1,405 underlying)
Footnotes (1)
- [F1]This is the weighted average price. The prices ranged from $18.40 to $18.86. The reporting person undertakes to provide on request a detailed breakout of the pricing.